https://www.amgen.com/newsroom/press-releases...ung-cancer
Many similarities here to LL's efforts.
With FDA approval, Jazz and Roche's combo sets new bar in first-line small cell lung cancer
Imdelltra’s success also marks a major breakthrough for T-cell engagers, which need to overcome an immunosuppressive tumor microenvironment and immune side effects to work in solid tumors. T-cell engagers, when used on their own, can cause the T cells to become exhausted. The addition of Imfinzi, a PD-L1 checkpoint inhibitor , helps rein in that mechanism and drive more durable responses, AZ’s Galbraith explained.
Burton described Imdelltra’s safety profile as “very manageable and […] very tolerable.” Even though half of patients in the Imdelltra-Imfinzi arm experienced cytokine release syndrome (CRS), only one (0.4%) reached grade 3, while the rest were managed by simple measures such as steroids.
Many similarities here to LL's efforts.
With FDA approval, Jazz and Roche's combo sets new bar in first-line small cell lung cancer
Imdelltra’s success also marks a major breakthrough for T-cell engagers, which need to overcome an immunosuppressive tumor microenvironment and immune side effects to work in solid tumors. T-cell engagers, when used on their own, can cause the T cells to become exhausted. The addition of Imfinzi, a PD-L1 checkpoint inhibitor , helps rein in that mechanism and drive more durable responses, AZ’s Galbraith explained.
Burton described Imdelltra’s safety profile as “very manageable and […] very tolerable.” Even though half of patients in the Imdelltra-Imfinzi arm experienced cytokine release syndrome (CRS), only one (0.4%) reached grade 3, while the rest were managed by simple measures such as steroids.
1
